|Bid||218.80 x 0|
|Ask||219.20 x 0|
|Day's Range||218.20 - 223.80|
|52 Week Range||125.20 - 297.20|
|Beta (5Y Monthly)||1.07|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 14, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||151.13|
·Commercial operations will be headquartered in Boston, as company looks to commercialize pipeline in the U.S. Copenhagen, DK and Boston, MA, U.S. July 6, 2020 – Zealand Pharma A/S (ZEAL.CO) (CVR-no. 20045078,) a biotechnology company changing lives with innovative peptide-based medicines, today announced the opening of its new U.S. headquarters in Boston which will be led by recently appointed President of Zealand Pharma U.S., Frank Sanders.
Zealand (ZEAL) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Zealand Pharma A/S (“Zealand”) (ZEAL.CO) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with Section 10 of the Danish Statutory Order on Issuers' Disclosure Obligations, announces the total number of shares and voting rights in the Company at the end of a calendar month during which there have been changes to its share capital. In Company announcement No. 32/2020 from June 12, 2020, Zealand announced an increase in share capital relating to the exercise of employee warrants, and in Company announcement No. 36/2020 from June 22, 2020, Zealand announced an increase in share capital relating to the completion of a private placement and directed issue of new shares.